Cargando…
Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment
PURPOSE: Many cancers lack argininosuccinate synthetase 1 (ASS1), the rate-limiting enzyme of arginine biosynthesis. This deficiency causes arginine auxotrophy, targetable by extracellular arginine-degrading enzymes such as ADI-PEG20. Long-term tumor resistance has thus far been attributed solely to...
Autores principales: | Rogers, Leonard C., Kremer, Jeff C., Brashears, Caitlyn B., Lin, Zongtao, Hu, Zhixian, Bastos, Alliny C.S., Baker, Adriana, Fettig, Nicole, Zhou, Dong, Shoghi, Kooresh I., Dehner, Carina A., Chrisinger, John S.A., Bomalaski, John S., Garcia, Benjamin A., Oyama, Toshinao, White, Eileen P., Van Tine, Brian A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425734/ https://www.ncbi.nlm.nih.gov/pubmed/37339179 http://dx.doi.org/10.1158/1078-0432.CCR-22-2642 |
Ejemplares similares
-
Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM
por: Przystal, Justyna Magdalena, et al.
Publicado: (2018) -
Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors
por: Yao, Shuyang, et al.
Publicado: (2021) -
Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia
por: Tsai, Hui‐Jen, et al.
Publicado: (2021) -
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies
por: Yao, Shuyang, et al.
Publicado: (2021) -
A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma
por: Chan, Pui Ying, et al.
Publicado: (2022)